Selutaront

Selutaront
Clinical data
Drug class	Trace amine-associated receptor 1 (TAAR1) agonist
Identifiers
	IUPAC name 12-methyl-3-thia-9,12-diazatricyclo[7.4.0.02,6]trideca-2(6),4-diene;
PubChem CID	171786782;
Chemical and physical data
Formula	C11H16N2S
Molar mass	208.32 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1CCN2CCC3=C(C2C1)SC=C3;
	InChI InChI=1S/C11H16N2S/c1-12-5-6-13-4-2-9-3-7-14-11(9)10(13)8-12/h3,7,10H,2,4-6,8H2,1H3; Key:HIEMMLQFNGZBMB-UHFFFAOYSA-N;

Selutaront is a trace amine-associated receptor 1 (TAAR1) agonist which is being investigated for the potential treatment of schizophrenia. It is a highly selective, low-potency, high-efficacy partial agonist of the human TAAR1 (EC₅₀Tooltip half-maximal effective concentration = 2,330 nM; E_maxTooltip maximal efficacy = 83%). The drug shows antipsychotic-like effects in rodents, such as antagonism of dizocilpine (MK-801)-induced hyperlocomotion, without affecting spontaneous locomotor activity when given by itself. The chemical synthesis of selutaront has been described. Selutaront was first described in the scientific literature by Jianzhao Zhang and colleagues in 2026.

See also